Innovative Therapeutics: Designer Natriuretic Peptides

JACC: Basic to Translational Science

Volumn 1, Issue 7, 2016, Pages 557-567

  Meems, Laura M G ^a   Burnett, John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

designer natriuretic peptide; drug development; heart failure; hypertension; natriuretic peptide

Indexed keywords

EID: 85016096253     PISSN: 2452302X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacbts.2016.10.001     Document Type: Review

References (83)

1. 1 Sidney, S., Quesenberry, C.P. Jr., Jaffe, M.G., et al. Recent trends in cardiovascular mortality in the United States and public health goals. JAMA Cardiol 1 (2016), 594–599.
2. 2 McMurray, J.J., Packer, M., Desai, A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
3. 3 Mangiafico, S., Costello-Boerrigter, L.C., Andersen, I.A., Cataliotti, A., Burnett, J.C. Jr., Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J 34 (2013), 886–893c.
4. 4 Ruilope, L.M., Dukat, A., Bohm, M., Lacourciere, Y., Gong, J., Lefkowitz, M.P., Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 375 (2010), 1255–1266.
5. 5 Jay, S.M., Lee, R.T., Protein engineering for cardiovascular therapeutics: untapped potential for cardiac repair. Circ Res 113 (2013), 933–943.
6. 6 Fosgerau, K., Hoffmann, T., Peptide therapeutics: current status and future directions. Drug Discov Today 20 (2015), 122–128.
7. 7 Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
8. 8 Rizzuti, M., Nizzardo, M., Zanetta, C., Ramirez, A., Corti, S., Therapeutic applications of the cell-penetrating HIV-1 Tat peptide. Drug Discov Today 20 (2015), 76–85.
9. 9 Teerlink, J.R., Cotter, G., Davison, B.A., et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381 (2013), 29–39.
10. 10 Levin, E.R., Gardner, D.G., Samson, W.K., Natriuretic peptides. N Engl J Med 339 (1998), 321–328.
11. 11 Bordicchia, M., Liu, D., Amri, E.Z., et al. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest 122 (2012), 1022–1036.
12. 12 Cannone, V., Boerrigter, G., Cataliotti, A., et al. A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. J Am Coll Cardiol 58 (2011), 629–636.
13. 13 Wang, T.J., The natriuretic peptides and fat metabolism. N Engl J Med 367 (2012), 377–378.
14. 14 Martinez-Rumayor, A., Richards, A.M., Burnett, J.C., Januzzi, J.L. Jr., Biology of the natriuretic peptides. Am J Cardiol 101 (2008), 3–8.
15. 15 van Kimmenade, R.R., Januzzi, J.L. Jr., The evolution of the natriuretic peptides - current applications in human and animal medicine. J Vet Cardiol 11:Suppl 1 (2009), S9–S21.
16. 16 Potter, L.R., Abbey-Hosch, S., Dickey, D.M., Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 27 (2006), 47–72.
17. 17 Takei, Y., Ogoshi, M., Inoue, K., A 'reverse’ phylogenetic approach for identification of novel osmoregulatory and cardiovascular hormones in vertebrates. Front Neuroendocrinol 28 (2007), 143–160.
18. 18 Fuller, F., Porter, J.G., Arfsten, A.E., et al. Atrial natriuretic peptide clearance receptor. Complete sequence and functional expression of cDNA clones. J Biol Chem 263 (1988), 9395–9401.
19. 19 Anand-Srivastava, M.B., Natriuretic peptide receptor-C signaling and regulation. Peptides 26 (2005), 1044–1059.
20. 20 Becker, J.R., Chatterjee, S., Robinson, T.Y., et al. Differential activation of natriuretic peptide receptors modulates cardiomyocyte proliferation during development. Development 141 (2014), 335–345.
21. 21 Moyes, A.J., Khambata, R.S., Villar, I., et al. Endothelial C-type natriuretic peptide maintains vascular homeostasis. J Clin Invest 124 (2014), 4039–4051.
22. 22 Kuhn, M., Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A. Circ Res 93 (2003), 700–709.
23. 23 Burnett, J.C. Jr., Granger, J.P., Opgenorth, T.J., Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol 247 (1984), F863–F866.
24. 24 Cataliotti, A., Chen, H.H., Schirger, J.A., et al. Chronic actions of a novel oral B-type natriuretic peptide conjugate in normal dogs and acute actions in angiotensin II-mediated hypertension. Circulation 118 (2008), 1729–1736.
25. 25 Nakagawa, H., Oberwinkler, H., Nikolaev, V.O., et al. Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation. Circ Heart Fail 7 (2014), 814–821.
26. 26 Schulz-Knappe, P., Forssmann, K., Herbst, F., Hock, D., Pipkorn, R., Forssmann, W.G., Isolation and structural analysis of “urodilatin”, a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klinische Wochenschrift 66 (1988), 752–759.
27. 27 Ichiki, T., Huntley, B.K., Sangaralingham, S.J., Burnett, J.C. Jr., Pro-atrial natriuretic peptide: a novel guanylyl cyclase-A receptor activator that goes beyond atrial and B-type natriuretic peptides. J Am Coll Cardiol HF 3 (2015), 715–723.
28. 28 Mills, R.M., Hobbs, R.E., Young, J.B., “BNP” for heart failure: role of nesiritide in cardiovascular therapeutics. Congest Heart Fail 8 (2002), 270–273.
29. 29 von Lueder, T.G., Sangaralingham, S.J., Wang, B.H., et al. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail 6 (2013), 594–605.
30. 30 Huntley, B.K., Sandberg, S.M., Heublein, D.M., Sangaralingham, S.J., Burnett, J.C. Jr., Ichiki, T., Pro-B-type natriuretic peptide-1-108 processing and degradation in human heart failure. Circ Heart Fail 8 (2015), 89–97.
31. 31 Maisel, A.S., Krishnaswamy, P., Nowak, R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347 (2002), 161–167.
32. 32 Januzzi, J.L., van Kimmenade, R., Lainchbury, J., et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 27 (2006), 330–337.
33. 33 McKie, P.M., Cataliotti, A., Lahr, B.D., et al. The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. J Am Coll Cardiol 55 (2010), 2140–2147.
34. 34 Sangaralingham, S.J., Wang, B.H., Huang, L., et al. Cardiorenal fibrosis and dysfunction in aging: imbalance in mediators and regulators of collagen. Peptides 76 (2016), 108–114.
35. 35 Schweitz, H., Vigne, P., Moinier, D., Frelin, C., Lazdunski, M., A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J Biol Chem 267 (1992), 13928–13932.
36. 36 van Jaarsveld, C.H., Ranchor, A.V., Kempen, G.I., Coyne, J.C., van Veldhuisen, D.J., Sanderman, R., Epidemiology of heart failure in a community-based study of subjects aged > or = 57 years: incidence and long-term survival. Eur J Heart Fail 8 (2006), 23–30.
37. 37 Macheret, F., Heublein, D., Costello-Boerrigter, L.C., et al. Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP. J Am Coll Cardiol 60 (2012), 1558–1565.
38. 38 McKie, P.M., Ichiki, T., Burnett, J.C. Jr., M-atrial natriuretic peptide: a novel antihypertensive protein therapy. Curr Hyperten Rep 14 (2012), 62–69.
39. 39 Hobbs, R.E., Miller, L.W., Bott-Silverman, C., James, K.B., Rincon, G., Grossbard, E.B., Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 78 (1996), 896–901.
40. 40 Colucci, W.S., Elkayam, U., Horton, D.P., et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 343 (2000), 246–253.
41. 41 Sackner-Bernstein, J.D., Kowalski, M., Fox, M., Aaronson, K., Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293 (2005), 1900–1905.
42. 42 Sackner-Bernstein, J.D., Skopicki, H.A., Aaronson, K.D., Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111 (2005), 1487–1491.
43. 43 O'Connor, C.M., Starling, R.C., Hernandez, A.F., et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365 (2011), 32–43.
44. 44 van Deursen, V.M., Hernandez, A.F., Stebbins, A., et al. Nesiritide, renal function, and associated outcomes during hospitalization for acute decompensated heart failure: results from the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF). Circulation 130 (2014), 958–965.
45. 45 Chen, H.H., Anstrom, K.J., Givertz, M.M., et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 310 (2013), 2533–2543.
46. 46 Cataliotti, A., Tonne, J.M., Bellavia, D., et al. Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats. Circulation 123 (2011), 1297–1305.
47. 47 McKie, P.M., Schirger, J.A., Benike, S.L., et al. Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure. Eur J Heart Fail 18 (2016), 433–441.
48. 48 Wan, S.H., McKie, P.M., Schirger, J.A., et al. Chronic peptide therapy with B-Type Natriuretic peptide in patients with pre-clinical diastolic dysfunction (stage B heart failure). J Am Coll Cardiol HF 4 (2016), 539–547.
49. 49 Chen, H.H., Glockner, J.F., Schirger, J.A., Cataliotti, A., Redfield, M.M., Burnett, J.C. Jr., Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. J Am Coll Cardiol 60 (2012), 2305–2312.
50. 50 Saito, Y., Roles of atrial natriuretic peptide and its therapeutic use. J Cardiol 56 (2010), 262–270.
51. 51 Suwa, M., Seino, Y., Nomachi, Y., Matsuki, S., Funahashi, K., Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the ‘real world’ of therapy. Circ J 69 (2005), 283–290.
52. 52 Nomura, F., Kurobe, N., Mori, Y., et al. Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated Heart Failure Study. Circ J 72 (2008), 1777–1786.
53. 53 Hata, N., Seino, Y., Tsutamoto, T., et al. Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study. Circ J 72 (2008), 1787–1793.
54. 54 Anker, S.D., Ponikowski, P., Mitrovic, V., Peacock, W.F., Filippatos, G., Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. Eur Heart J 36 (2015), 715–723.
55. 55 Abassi, Z.A., Powell, J.R., Golomb, E., Keiser, H.R., Renal and systemic effects of urodilatin in rats with high-output heart failure. Am J Physiol 262 (1992), F615–F621.
56. 56 Chen, H.H., Cataliotti, A., Schirger, J.A., Martin, F.L., Burnett, J.C. Jr., Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure. Am J Physiol Regul, Integ Comp Physiol 288 (2005), R1093–R1097.
57. 57 Kentsch, M., Ludwig, D., Drummer, C., Gerzer, R., Muller-Esch, G., Haemodynamic and renal effects of urodilatin bolus injections in patients with congestive heart failure. Eur J Clin Invest 22 (1992), 66–69.
58. 58 Mitrovic, V., Luss, H., Nitsche, K., et al. Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial. Am Heart J, 150, 2005, 1239.
59. 59 Luss, H., Mitrovic, V., Seferovic, P.M., et al. Renal effects of ularitide in patients with decompensated heart failure. Am Heart J 155 (2008), 1012.e1–1012.e8.
60. 60 Patel, J.B., Valencik, M.L., Pritchett, A.M., Burnett, J.C. Jr., McDonald, J.A., Redfield, M.M., Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload. Am J Physiol Heart Circ Physiol 289 (2005), H777–H784.
61. 61 Lee, C.Y., Huntley, B.K., McCormick, D.J., et al. Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions. Eur Heart J Cardiovasc Pharm 2 (2016), 98–105.
62. 62 Dickey, D.M., Yoder, A.R., Potter, L.R., A familial mutation renders atrial natriuretic peptide resistant to proteolytic degradation. J Biol Chem 284 (2009), 19196–19202.
63. 63 Lisy, O., Huntley, B.K., McCormick, D.J., Kurlansky, P.A., Burnett, J.C. Jr., Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol 52 (2008), 60–68.
64. 64 McKie, P.M., Cataliotti, A., Huntley, B.K., Martin, F.L., Olson, T.M., Burnett, J.C. Jr., A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions. J Am Coll Cardiol 54 (2009), 1024–1032.
65. 65 Pan, S., Chen, H.H., Dickey, D.M., et al. Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide. Proc Natl Acad Sci U S A 106 (2009), 11282–11287.
66. 66 Wei, C.M., Kim, C.H., Miller, V.M., Burnett, J.C. Jr., Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide. J Clin Invest 92 (1993), 2048–2052.
67. 67 Feng, H.S., Zang, Y.M., Zhu, M.Z., et al. [Comparison of vasorelaxing actions of vasonatrin peptide, C-type natriuretic peptide and atrial natriuretic peptide]. Sheng li xue bao [Acta Physiol Sinica] 51 (1999), 515–520.
68. 68 Yu, J., Zhu, M.Z., Wei, G.Z., et al. [Vasorelaxing role of vasonatrin peptide in human intramammary artery in vitro]. Sheng li xue bao [Acta Physiol Sinica] 55 (2003), 187–190.
69. 69 Dong, M.Q., Zhu, M.Z., Yu, J., Shang, L.J., Feng, H.S., [Comparison of inhibitory effects of three natriuretic peptides on the proliferation of pulmonary artery smooth muscle cells of rats]. Sheng li xue bao [Acta Physiol Sinica] 52 (2000), 252–254.
70. 70 Dickey, D.M., Burnett, J.C. Jr., Potter, L.R., Novel bifunctional natriuretic peptides as potential therapeutics. J Biol Chem 283 (2008), 35003–35009.
71. 71 Martin, F.L., Sangaralingham, S.J., Huntley, B.K., et al. CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart. PloS One, 7, 2012, e52422.
72. 72 Ichiki, T., Schirger, J.A., Huntley, B.K., et al. Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: regulation and therapeutic implications. J Mol Cell Cardiol 75 (2014), 199–205.
73. 73 Lee, C.Y., Chen, H.H., Lisy, O., et al. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J Clin Pharmacol 49 (2009), 668–673.
74. 74 Lim, J., Clements, M.A., Dobson, J., Delivery of short interfering ribonucleic acid-complexed magnetic nanoparticles in an oscillating field occurs via caveolae-mediated endocytosis. PloS One, 7, 2012, e51350.
75. 75 Ng, X.W., Huang, Y., Chen, H.H., Burnett, J.C. Jr., Boey, F.Y., Venkatraman, S.S., Cenderitide-eluting film for potential cardiac patch applications. PloS One, 8, 2013, e68346.
76. 76 Le, K.Q., Prabhakar, B.S., Hong, W.J., Li, L.C., Alternative splicing as a biomarker and potential target for drug discovery. Acta Pharmacol Sinica 36 (2015), 1212–1218.
77. 77 Wright, J.T. Jr., Williamson, J.D., Whelton, P.K., et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373 (2015), 2103–2116.
78. 78 Buglioni, A., Cannone, V., Cataliotti, A., et al. Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease. Hypertension 65 (2015), 45–53.
79. 79 Dickey, D.M., Potter, L.R., Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation. J Mol Cell Cardiol 51 (2011), 67–71.
80. 80 McKie, P.M., Cataliotti, A., Boerrigter, G., et al. A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension. Hypertension 56 (2010), 1152–1159.
81. 81 McKie, P.M., Cataliotti, A., Ichiki, T., Sangaralingham, S.J., Chen, H.H., Burnett, J.C. Jr., M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics. J Am Heart Assoc, 3, 2014, e000206.
82. 82 Buglioni, A., Scott, C.G., Bailey, K.R., Rodeheffer, R.J., Sarzani, R., Burnett, J.C., Aldosterone levels, atrial natriuretic peptide and resistant hypertension in the general community. J Am Soc Hyperten, 10, 2016, e40.
83. 83 Chen, H.H., Neutel, J., Smith, D., Heublein, D., Burnett, J., A first-in-human trial of a novel designer natriuretic peptide ZD100 in human hypertension. J Am Soc Hyperten, 10, 2016, e23.